Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Capital Employed (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Return on Capital Employed readings, the most recent being 67.62% for Q4 2025.

  • On a quarterly basis, Return on Capital Employed fell 938.0% to 67.62% in Q4 2025 year-over-year; TTM through Dec 2025 was 67.62%, a 938.0% decrease, with the full-year FY2025 number at 60.44%, up 2639.0% from a year prior.
  • Return on Capital Employed hit 67.62% in Q4 2025 for Avalo Therapeutics, down from 56.41% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 35.81% in Q1 2024 to a low of 291.53% in Q4 2022.
  • Median Return on Capital Employed over the past 5 years was 136.9% (2022), compared with a mean of 151.9%.
  • Biggest five-year swings in Return on Capital Employed: crashed -17056bps in 2022 and later soared 25543bps in 2024.
  • Avalo Therapeutics' Return on Capital Employed stood at 120.97% in 2021, then plummeted by -141bps to 291.53% in 2022, then surged by 54bps to 133.33% in 2023, then soared by 56bps to 58.24% in 2024, then dropped by -16bps to 67.62% in 2025.
  • The last three reported values for Return on Capital Employed were 67.62% (Q4 2025), 56.41% (Q3 2025), and 48.79% (Q2 2025) per Business Quant data.